Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
Health Care Businesses
First-of-a-kind drug approvals continued rise in 2015
The rising figures reflect an industry-wide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
IU Health shuffles execs in advance of Evans’ retirement
The state’s largest hospital system will promote IU Health Arnett President Al Gatmaitin president to chief operating officer, replacing Dennis Murphy, who is set to become CEO in April.
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Startup for therapeutic gear raises $3M on way to market
Fishers-based Recovery Force LLC, which develops high-tech compression wearables for medical patients, athletes and military members, is working toward FDA approval.
Lilly separating manufacturing of animal health drugs
Eli Lilly and Co. is in the process of separating the manufacturing of its animal health drugs from the facilities used to make its traditional pharmaceuticals, a move that potentially could make it easier to spin off the division one day.
Pfizer-Allergan $160B deal forms world’s largest drugmaker
It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.
U.S. doctors group calls for drug advertising ban
In a vote Tuesday, the American Medical Association called for an end to television commercials and magazine spreads that are used to pitch prescription drugs directly to consumers.
Despite wealth of attention, new female libido pill isn’t selling
The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227.
Lilly, other drugmakers face federal pricing probe
Indianapolis-based Eli Lilly and Co. and other U.S. drugmakers are being investigated by federal prosecutors over their drug-pricing practices related to Medicare and Medicaid, according to newspaper reports.
Mainstreet engineers reverse takeover of public Canadian firm
Carmel-based Mainstreet has engineered a $302.5 million reverse takeover of a Canadian long-term care company that will once again give Mainstreet a publicly traded investment firm to help finance its development projects.
Caregivers see need for more pint-sized medical devices
Companies—including Indiana-based OrthoPediatrics Corp.—are starting to answer parents’ call for more help for children.
Elanco president makes case for juiced-up cows in organic age
Jeff Simmons is on a counteroffensive as, increasingly, the drugs that Elanco makes—including antibiotics and productivity enhancers—have come under attack by food activists.
Soaring Rx costs lift firm’s prospects, job creation
Rx Help Centers assists employers and customers as they navigate through the confusing web of prescription drug discounts. Business is so good that the company hopes to add 250 workers by 2017.
Pharmaceutical firms losing business to darknet drug deals
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.
Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Cook executive, daughter die in plane crash
William S. Gibbons Jr., Cook's vice president of of global engineering, and his 15-year-old daughter, Abbey, were killed when the plane crashed into Buffalo Mountain in eastern Tennessee.
UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Lilly expands China drug partnership in growing cancer market
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Lilly to add 50 employees at R&D center in New York
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.